Skip to main navigation Skip to search Skip to main content

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Research output: Contribution to journal › Article › peer-review

631 Scopus citations

Fingerprint

Dive into the research topics of 'Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science